Abstract:
Objective :To discuss the outcoming of treating with mitomycin C(MMC) after TUVBt as a treatment of superficial bladder carcinoma.Method:Retrospectively study of 46 cases from 1999 to 2005,underwent TUVBT.Result:Postoperation all the patients received mitomycin C(MMC) intravesical instillation.no one was recurrence in 33 cases followup duration 36 months,7 case recurrence.Conclusion :TUVBT is less invasive,with clear visual field,definitive resection depth,and less recurrence in treatment of superficial bladder carcinoma.Keywords:
Mitomycin C
Cite
Mitomycin C
Urothelial cancer
Cite
Citations (0)
Objectives To evaluate the safety and efficacy of 2μm laser resection in combination with intravesical instillation of mitomycin for treatment of superficial bladder cancer.Methods From June.2009 to June.2012,116 patients with superficial bladder cancer,18 cases of high grade urothelial papillary carcinoma,93 low grade urothelial papillary carcinoma and 5 papillary urothelial neoplasm with low malignant potential,were enrolled in our institute.Imaging methods including CT scan and intravenous pyelography,were performed to exclude extravesical invasion,involvement of lymph nodes and tumor in upper urinary tract.Tumors were resected successfully in patients with 2μm laser under epidural anesthesia.Immediate intravesical instillation of mitomycin was applied in all patients followed with 8 weekly and 10 monthly doses of mitomycin maintenance therapy.Results Total 201 tumors in 106 patients were resected successfully and mean operation time of every patient was 28 minutes.No obturator nerve reflex and severe perforation occurred.All patients underwent 12 months of intravesical mitomycin and tumor recurrence was found in 9.5％ patients.Conclusions 2μ m laser in combination with mitomycin intravesical instillation was safe and effective for treatment of superficial bladder cancer.
Key words:
Urinary Bladder; Neoplasms; Mitomycin Lasers
Mitomycin C
Obturator nerve
Cite
Citations (0)
Objective To evaluate the effectiveness and safety of intravesically instilling pirarubicin(THP) and mitomycin C(MMC) after transurethral resection of bladder tumor(TURBT) of superficial bladder cancer in prevention of tumor recurrence.Methods Eighty patients of superficial bladder cancer after TURBT were divided into 2 groups with randomized block design(40 cases in each group).The patients received intravesical treatment with THP and MMC in 2 groups,respectively.All patients were followed up for 12-36 months,and the recurrence rate and adverse reactions were recorded.Results Recurrence rate was 15.0% for THP and 17.5% for MMC,and the difference was not significant statistically(P0.05).The incidence rates of chemical cystitis were 42.5% in THP group and 30% in MMC group(P0.05).No urethral stricture,leukopenia and liver and kidney dysfunction were observed in both groups.Conclusion THP and MMC have the similar efficacy in prevention of recurrence of superficial bladder cancer by intravesical instillation after TURBT.The adverse drug reactions are tolerable and no systemic reaction is observed.
Pirarubicin
Mitomycin C
Leukopenia
Bladder tumor
Cite
Citations (0)
Objective To discuss the outcome of mitomycin C(MMC) after TURBT as a treatment of non-muscle invasive bladder cancer.Methods Retrospectively study of 46 cases from 2004 to 2007,underwent TURBT and MMC intravesical instillation.Results All non-muscle invasive bladder cancers were resected completely.All patients received MMC intravesical instillation affer operation.Follow-up for 2 years,7 cases recurred in 1 year,2 cases recurred in 2 years.All recurred cases received TURBT and MMC intravesical instillation.No recurrence found in other 37 cases.Conclusions TURBT is less invasive,with clear visual field definitive resection depth,and less recurrence in treatment of non-muscle invasive bladder cancer.MMC intravesical instillation can significantly reduce non-muscle invasive bladder cancer recurrence rate.
Mitomycin C
Bladder tumor
Cite
Citations (0)
Objective To investigate the effects of intravesical instillation on the recurrence of bladder tumor after transurethral resection of superficial bladder cancer.Methods 130 patients underwent transurethral resection of superficial bladder cancer(T0-T1) and postoperative intravesical instillation of chemotherapeutic drugs in our department during Feb.2007 to Oct.2009.Among them,70 patients received mitomycin and 60 pirarubicin.One-year recurrence rate and side-effects of intravesical instillation of mitomycin and pirarubicin were analyzed.Results One-year recurrence rate was 11.4% in the mitomycin group and 16.7% in the pirarubicin group(P0.05).One-year recurrence rates of grade G1,G2,and G3 tumor were 12.2%,8%,and 25% in the mitomycin group and 4%,12.5%,and 54.5% in the pirarubicin group.Patients received immediate postoperative instillation of mitomycin or pirarubicin had a lower rate of recurrence [4%(1/25)] than those who didn't receive immediate instillation [16.2%(17/105),P0.05].The systemic side-effects of mitomycin and pirarubicin were 18.5% and 1.5%(P0.05),and the local side-effects were 4.3% and 33.3%(P0.05).Conclusions The one-year recurrence rate is similar in patients with postoperative intravesical instillation of mitomycin and those with pirarubicin and chemotherapeutic drugs.Postoperative instillation of chemotherapeutic drugs is not effective on G3 tumor recurrence.Intravesical instillation of mitomycin mainly results in systemic reaction and pirarubicin mainly causes local reaction.
Pirarubicin
Mitomycin C
Cite
Citations (0)
Abstract Background: A recurrence of bladder tumors following surgery for transitional cell carcinoma of the upper urinary tract is not rarely observed. A prospective randomized study was conducted to examine the significance of prophylactic intravesical instillation of mitomycin C (MMC) and cytosine arabinoside (Ara‐C) to prevent recurrent bladder tumors after surgery for superficial transitional cell carcinoma of the upper urinary tract. Methods: The patients were randomized into an instillation group, who received postoperative intravesical instillation of MMC (20 mg) and Ara‐C (200 mg) 28 times over a period of 2 years, and a non‐instillation group. The non‐recurrence rate was then compared between the groups. Results: Of the 27 patients registered, 25 patients (13 with instillation and 12 without instillation) were able to be evaluated, with a median follow‐up period of 45 months. The non‐recurrence rate of bladder tumors in the instillation group was higher than that in the non‐instillation group. Although the difference was not statistically significant, the P ‐value ( P = 0.079) demonstrated a strong trend. When any possible bias was allowed for a multivariate analysis, the difference was almost significant ( P = 0.0567). No patients withdrew from this study due to any side‐effects. Conclusion: The postoperative instillation of MMC and Ara‐C may be a useful approach for reducing the recurrence of bladder tumors after surgery for upper urinary tract tumors.
Mitomycin C
Upper urinary tract
Cite
Citations (50)
Cite
Citations (0)
Objective To discuss the outcome of mitomycin C(MMC)after TURBT as a treatment of superficial bladder carcinoma.Methods 62 cases underwent TURBT and mitomycin C intravesical instillation were analyzed.Results All bladder carcinomas were a completely resection.Postoperation al1 the patients received mitomycin C(MMC) intravesical instillation.No one was recurrence in 54 cases after 7 to 72 months follow up(87%),6 cases recurrence during 1 year,2 cases recurrence during 2 years.One case recurrence three times within 4 years.The patients received TURBT and mitomycin C intravesical instillation.Conclusion TURBT is less invasive,with clear visual field.definitive resection depth.and less recurrence in treatment of superficial bladder carcinoma.Mitomycin C intravesical instillation can significantly reduce superficial bladder cancer recurrence.
Mitomycin C
Bladder tumor
Cite
Citations (0)
Objective To investigate the effect of intravesical instillation of MMC plus IFNα-2b on preventing postoperation recurrence of bladder cancer. Methods Eighty-two patients with bladder cancer were treated by conservative bladder operations including TURBt and partial cystectomy, followed by postoperative intravesical instillation of MMC plus IFN α-2b (therapy group),and 68 cases treated by conservative bladder operations were followed by postoperative intravesical instillation of MMC alone(control group). Results The recurrence rate of therapy group was 7.6%(6/79),and that of control group was 20.6%(14/68).There was significant difference between the two groups(P0.05). Conclusion The effect of intravesical instillation of MMC plus IFNα-2b on preventing postoperation recurrence of bladder cancer is better than that of MMC alone.
Bladder Neoplasm
Cite
Citations (0)
Objective:To observe the clinical effects of transurethral resection of the bladder tumor in combination with pirarubicin intravesical instillation immediatelyin on the treatment of superficial bladder carcinoma.Methods:Seventy-five cases of superficial bladder carcinomas were treated with transurethral resection of the bladder tumor and pirarubicin intravesical instillation immediately after operation.Results:All cases received a complete resection.During a follow-up period of 2 years,58 cases had no recurrence,12 cases had recurrence after one year and 5 cases had recurrence after two years.Conclusion:The treatment of transurethral resection of the bladder tumor in combination with pirarubicin intravesical instillation for superficial bladder carcinoma is effective and simple,and worthy spreading.
Pirarubicin
Bladder tumor
Cite
Citations (0)